source
- Roche partners with China's Simcere Zaiming on $1.5 billion T-cell engager for B-cell diseasesRoche announced a licensing agreement with Simcere Zaiming, a subsidiary of China's Simcere Pharmaceutical Group, to develop a trispecific T-cell engager called SIM0660. The deal includes an upfro…
- GSK to start Phase 3 trial of mRNA flu vaccine after strong mid-stage resultsGSK announced it will begin a Phase 3 trial of its mRNA-based influenza vaccine, with enrollment slated to start in September. In a Phase 2 study of 971 adults, the investigational vaccine, which…